DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY
Clinical trials for DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY explained in plain language.
Never miss a new study
Get alerted when new DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY trials appear
Sign up with your email to follow new studies for DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat seizures: phase 3 trial launches
Disease control OngoingThis study tests an experimental drug called LP352 to see if it can safely reduce seizures in children and adults with developmental and epileptic encephalopathies (DEE), a group of severe epilepsy syndromes. About 320 participants will receive either LP352 or a placebo, and rese…
Matched conditions: DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY
Phase: PHASE3 • Sponsor: Longboard Pharmaceuticals • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug LP352 aims to control seizures in severe epilepsy over the long term
Disease control ENROLLING_BY_INVITATIONThis phase 3 study is testing the long-term safety and effectiveness of LP352 (Bexicaserin) in 324 children and adults with developmental and epileptic encephalopathy (DEE), including Dravet and Lennox-Gastaut syndromes. Participants who completed earlier studies will receive LP3…
Matched conditions: DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY
Phase: PHASE3 • Sponsor: Longboard Pharmaceuticals • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for kids with rare epilepsy: drug trial targets seizure control
Disease control OngoingThis study tests an investigational drug called relutrigine in 160 children with a severe form of epilepsy called developmental and epileptic encephalopathy (DEE). The goal is to see if the drug can safely reduce monthly seizure frequency compared to a placebo. After the initial …
Matched conditions: DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY
Phase: PHASE3 • Sponsor: Praxis Precision Medicines • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Could a urea cycle drug help kids with rare epilepsy?
Disease control OngoingThis early-phase trial is testing whether glycerol phenylbutyrate (Ravicti), a drug already approved for a different condition, is safe and tolerable for children with genetic disorders like STXBP1 and SLC6A1 that cause seizures and developmental delays. The study will enroll 50 …
Matched conditions: DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY
Phase: EARLY_PHASE1 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC